apixaban Articles
Decline in cardiovascular drugs noted at ESC congress
17 September 2012
Bristol-Myers and Pfizer’s Eliquis first oral anticoagulant to significantly reduce all-cause death
30 August 2011
Bristol-Myers Squibb and Pfizer drop development of apixaban in acute coronary syndrome, but good news for Pfizer with axitinib
22 November 2010
Two blockbuster potential stroke/DVT drugs report good results at ESC Congress: Bristol-Myers/Pfizer’s apixaban and Bayer/J&J’s rivaroxaban
1 September 2010
Early closing of apixaban trial on good results in AF sees Pfizer and Bristol-Myers Squibb shares rise
14 June 2010
Novel oral anticoagulants will drive venous thromboembolism market to nearly double by 2018
1 April 2010
Showing 1-7 of 7 articles
- 1
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Is failure to adopt business process management putting the pharma industry at risk?
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
